Aadel Chaudhuri, MD, PhD, began his scientific training at MIT in the laboratory of Nobel Laureate Phillip Sharp and continued at Caltech with Nobel Laureate David Baltimore, where he led foundational studies on microRNAs in cancer and immunity. During residency and postdoctoral training at Stanford under ASCI and National Academy of Medicine member Maximilian Diehn, he led a seminal Cancer Discovery study introducing the concept of circulating tumor DNA (ctDNA) minimal residual disease (MRD). This work demonstrated that ctDNA can detect residual disease months before radiographic progression and helped establish the foundation for ctDNA-guided molecular response assessment, now widely incorporated into clinical trials and commercial diagnostic platforms.

Dr. Chaudhuri now leads the Liquid Biopsy and Translational Immunogenomics Laboratory at Mayo Clinic. His group develops and clinically translates integrative liquid biopsy strategies, leveraging genomic, epigenomic, fragmentomic, and immune repertoire profiling of human biofluids to enable early cancer detection, dynamic treatment monitoring, and prediction of therapeutic response and resistance. His work has advanced ctDNA MRD detection using plasma, urine, and lymph-derived biofluids, as well as noninvasive profiling of tumor–immune dynamics from circulation. His research program is supported by six NIH R01/R35/U01 awards of which he is PI.

Dr. Chaudhuri serves as Professor and Vice Chair for Translational Research in Radiation Oncology and as Enterprise Co-Leader of Mayo Clinic’s Cancer Precision Medicine Office. Deeply committed to mentorship and the development of physician-scientists, he trains graduate and medical students and serves on Mayo Clinic’s MD/PhD program admissions committee.